Phase IIb Study of MP4OX in Traumatic Hemorrhagic Shock Patients
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
MP4OX is a novel oxygen therapeutic agent being developed as an ischemic rescue therapy to
enhance perfusion and oxygenation of tissues at risk during hemorrhagic shock. MP4OX is a
pegylated hemoglobin-based colloid. Due to its molecular size and unique oxygen dissociation
characteristics, MP4OX targets delivery of oxygen to ischemic tissues. This study will
evaluate the safety and efficacy of MP4OX treatment in trauma patients suffering from lactic
acidosis due to severe hemorrhagic shock. The study hypothesis is that MP4OX will reverse the
lactic acidosis by enhancing perfusion and oxygenation of ischemic tissues and thereby
prevent and reduce the duration of organ failure and improve outcome in these patients.